Cue Biopharma, Inc. (CUE)
 NASDAQ: CUE · Real-Time Price · USD
 0.6994
 +0.0094 (1.36%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Cue Biopharma Employees
Cue Biopharma had 41 employees as of December 31, 2024. The number of employees decreased by 12 or -22.64% compared to the previous year.
Employees 
 41
Change (1Y) 
 -12
Growth (1Y) 
 -22.64%
Revenue / Employee 
 $202,098
Profits / Employee 
 -$948,659
Market Cap 
53.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 41 | -12 | -22.64% | 
| Dec 31, 2023 | 53 | 1 | 1.92% | 
| Dec 31, 2022 | 52 | -7 | -11.86% | 
| Dec 31, 2021 | 59 | 7 | 13.46% | 
| Dec 31, 2020 | 52 | 5 | 10.64% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
CUE News
- 4 weeks ago - Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates - GlobeNewsWire
- 2 months ago - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - GlobeNewsWire
- 2 months ago - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - GlobeNewsWire
- 4 months ago - Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire
- 4 months ago - Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease - GlobeNewsWire
- 6 months ago - Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire